Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Reimagining the Smart Hospital, Cleveland Clinic Style
Cleveland Clinic’s chief information officer, Sarah Hatchett, says a truly smart hospital hinges on orchestrating a seamless, longitudinal patient journey rather than simply installing the latest devices. At HIMSS26, the health system showcased how AI‑driven analytics pull in pre‑admission data to tailor care pathways before a patient even steps through the door. The initiative relies on a robust, low‑latency network that links clinical, operational and administrative teams in real time. By embedding intuitive tools and focused training, Cleveland Clinic aims to boost staff adoption and translate digital integration into measurable outcome gains.
Beyond Tools: Joydeep Ganguly on Building End-to-End 4IR Supply Chains
Pharma supply chains are hitting a complexity inflection point, with DSCSA enforcement and the rise of temperature‑sensitive therapies demanding tighter visibility and traceability. Joydeep Ganguly, Agilent’s chief operations and quality officer, told LogiPharma Europe 2026 that successful 4IR adoption starts with a...
Codeine: Why One Person’s Painkiller Can Be Another Person’s Problem
Codeine, a weak opioid commonly sold OTC in the UK, is metabolised into morphine by the liver enzyme CYP2D6, creating wide variability in its effectiveness and safety. Genetic differences mean ultra‑rapid metabolisers (1‑2% of the population) can experience dangerously high...
No More Flu Shot Mandate… Now What?
The U.S. military has lifted its universal flu‑shot mandate, ending a policy that has existed since the Revolutionary War. The change signals a shift toward greater respect for individual autonomy and informed consent, even in a highly communal environment. While...
Medicare AI Prior Authorization Pilot Delaying Care in Washington: Report
A Medicare pilot that uses artificial‑intelligence‑driven prior authorizations—known as the WISeR model—has stretched approval times in Washington from roughly two weeks to four‑to‑eight weeks. The delay, documented by the Washington State Hospital Association, is forcing providers to add staff and...
Broker’s Call: Fortis Healthcare (Buy)
Motilal Oswal initiates coverage on Fortis Healthcare with a Buy rating, setting a target of ₹1,100 (≈ $13) versus the current price of ₹928.10 (≈ $11). Since IHH Healthcare took over in FY‑19, the hospital chain has cleaned up its balance sheet,...
Exclusive: UC Berkeley Startup Bets on Jumping Genes for GLP-1 Gene Therapy
A UC Berkeley spin‑out is developing a gene‑therapy platform that inserts a GLP‑1‑producing cassette into patients' cells using a jumping‑gene (transposon) system. The approach seeks to turn the body into its own continuous source of the hormone, eliminating the need...
Alcohol Causes More Cancers in Australia than Previously Thought
A University of Sydney study published in the British Journal of Cancer estimates that 4.6% of all cancers in Australia—about 7,800 cases in 2024—are attributable to alcohol, higher than previous 2.8‑4.1% estimates. Overall cancer risk rises 19% with alcohol consumption,...
AAN 2026: Long Half-Life and Long-Acting Injectable, What Pharmacists Should Know About RAP-219's Dosing Advantages for Focal Epilepsy
Rapport Therapeutics presented phase 2 data for RAP‑219 at the AAN 2026 meeting, showing 24% of drug‑resistant focal epilepsy patients achieved complete seizure freedom over an eight‑week period. The trial leveraged responsive neurostimulation (RNS) devices to capture objective electrographic seizure data,...
Interoperability Governance Gaps Put Pressure on Nationwide Exchange Networks
Health Gorilla CEO Bob Watson warns that nationwide health‑information exchange networks are being asked to govern data at a scale they were never designed for. He recommends a federally overseen, industry‑funded credentialing authority to standardize onboarding, reduce fraud risk, and...
Bristol Myers Squibb and Pfizer to Make Eliquis® (Apixaban) Available via Mark Cuban Cost Plus Drug Company
Bristol Myers Squibb and Pfizer announced that their joint‑venture will sell Eliquis® (apixaban) through Mark Cuban’s Cost Plus Drugs platform starting April 27, 2026. Cash‑pay patients can purchase a 30‑day supply for $345, a price positioned below many insurance copays. The move expands the...
Pharma & Biotech Patent Litigation in Europe Conference Returns with IPKat Readers’ Discount
The Pharma & Biotech Patent Litigation in Europe conference returns for a two‑day session in central Amsterdam. Organisers highlight a special 10% discount for IPKat readers using code D10‑999‑IPKAT26. The agenda tackles hot topics such as cross‑border enforcement after the...
New Antibody Drugs Target Disease From Within
Researchers have used AI to redesign antibody binding fragments, creating more than 600 stable intracellular versions. By adjusting charge distribution, these fragments remain soluble inside cells and retain target specificity, enabling direct binding to disease‑driving proteins such as those implicated...
What Makes AI a Friend, Foe or Time Thief in Radiology?
Artificial intelligence is reshaping radiology, but its value depends on how hospitals manage it after FDA clearance. Emory’s Dr. Patricia Balthazar warns that post‑deployment monitoring, workflow integration, and governance are critical to avoid performance drift. She highlights recent server‑routing glitches...
Regulatory Round-Up: Novartis, Sanofi and Arrowhead Secure CHMP Blessings
The European Committee for Medicinal Products (CHMP) issued positive opinions on three therapies: Sanofi's BTK inhibitor cenrifki for non‑relapsing secondary progressive multiple sclerosis, Arrowhead's siRNA drug redemplo for familial chylomicronemia syndrome, and Novartis' gene‑replacement therapy itvisma for spinal muscular atrophy....
Jefferies Updates Elevance Health, Inc. (ELV) Forecasts After Deeper Analysis of Exchange Segment Dynamics
Jefferies analyst David Windley trimmed Elevance Health’s (ELV) price target to $391 from $395, citing a deeper review of the health‑insurance exchange segment. The revision accompanies updated financial forecasts that reflect refined assumptions about managed‑care plan dynamics. In March, Elevance...
Evercore ISI Says Sun Pharma Deal Talk for Organon & Co. (OGN) Lacks Confirmation, Remains Speculative
Evercore ISI said media reports of a potential $12 billion Sun Pharmaceutical offer for Organon & Co. are speculative and lack confirmation. The firm emphasized that the rumor does not constitute a confirmed transaction. Separately, Organon’s VTAMA (tapinarof) 1% cream received...
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
Merck announced that the Hart‑Scott‑Rodino antitrust waiting period for its pending acquisition of Terns Pharmaceuticals expired at 11:59 p.m. ET on April 23, 2026. The company’s cash tender offer, launched on April 7, proposes to buy each Terns share for $53 in cash, less...
Inspire Medical Systems, Inc. (INSP) PT Reduced to $64 as Truist Updates MedTech Outlook Ahead of Q1
Truist Financial trimmed its price target for Inspire Medical Systems (INSP) to $64 from $70, while keeping a Hold stance, as part of a broader MedTech outlook ahead of the company’s Q1 earnings. A day earlier, Royal Bank of Canada...
Insurers Profit From Rising Costs, yet Add Little Value
Insurers are not directly the primary cause of health spending growth. But, with major insurers posting strong profits as health care costs grow, it’s reasonable to ask what value they provide for the overhead they consume. https://jamanetwork.com/journals/jama-health-forum/fullarticle/2848374
The Cancer Crisis We Can See Coming And Have the Tools to Change
Colorectal cancer has become the leading cause of cancer death for Americans under 50, with survival dropping sharply when diagnosis is delayed. A one‑month postponement of treatment raises mortality risk by more than 12 %, and a three‑month delay can increase...
STAT+: Pharmalittle: We’re Reading About a Trump Deal with Regeneron, Reclassifying Medical Marijuana, and More
President Trump sealed a private drug‑pricing pact with Regeneron, securing lower Medicaid prices, a $225 price point for Praluent, and a $27 billion commitment to U.S. drug development. The agreement also coincided with FDA approval of Otarmeni, the first gene therapy...
Precision Delivered: How Radiopharmaceuticals Are Reshaping Cancer Care
Radiopharmaceuticals, especially alpha‑emitting agents, are emerging as precision tools that deliver high‑LET radiation directly to cancer cells while sparing healthy tissue. Building on decades of beta‑emitter use, alpha therapies generate dense DNA damage and are less dependent on tumor oxygenation....
‘What the Health?’ Podcast: RFK Jr. Vs. Congress
HHS Secretary Robert F. Kennedy Jr. wrapped a House and Senate committee tour aimed at selling President Donald Trump’s health‑budget proposal while fielding questions on his outspoken vaccine views. The same week, Trump signed an executive order to streamline the use of hallucinogenic...
A Fifth Diabetes Type Redefines Medical Textbooks
A Fifth Type of Diabetes Was Just Officially Recognized -- and It Breaks the Textbook Most of the world learns two types of diabetes. The International Diabetes Federation just recognized a fifth. As a medical school professor, I teach that our disease...
Midlife Vitamin D Deficiency Forecasts Tau Build‑Up 16 Years Later
Many papers associate low vitamin D levels w/ worse health outcomes. What's notable about this new study is how long subjects were followed: Low vitamin D in midlife predicted tau burden on PET 16 years later. https://t.co/rUWJGbZBgl https://t.co/Qf5z8ueKyp
ChildObesity180 Secures $9.8M to Accelerate Systemic Fight Against Childhood Obesity
ChildObesity180, the nonprofit born from Tufts University's Friedman School, has obtained a $1.3 million NIH grant with New York Road Runners and an $8.5 million USDA tele‑health award for WIC. The funding will expand school‑based and home‑focused programs that have already touched more...
Understanding CDC, MAHA: US Public Health Outlook
We're talking CDC, MAHA and what it all means for public health in the US -- today at 11am ET with @WSITYpod + @maxonwifi https://t.co/2ClZf4225D
US Military's Flu Vaccine Legacy Undermined by Dropping Mandates
Motivated by the devastation the Spanish flu inflicted on WW1 troops, the US military was key in the development of #flu vaccine. Keeping troops battle ready is critical, which makes Hegseth's decision to drop mandatory flu shots ill-advised, Paul Friedrichs...
Duodenal Mucosal Resurfacing Cuts Weight Regain After Ozempic Stop, Trial Shows
A blinded, sham‑controlled trial presented at Digestive Disease Week 2026 shows duodenal mucosal resurfacing (DMR) reduces weight regain after discontinuing GLP‑1 drugs like Ozempic. In 45 participants, those receiving DMR kept over 80% of their loss, while sham controls regained...
Agios Shares Plunge 27% After Novo Nordisk Announces Superior Sickle‑Cell Results
Agios Pharmaceuticals' shares tumbled 26.8% after Novo Nordisk disclosed Phase 3 data showing its etavopivat outperformed Agios' mitapivat in sickle‑cell disease. The setback comes as Agios reported a $1.1 billion milestone boost from vorasidenib approval but faces uncertainty over mitapivat’s accelerated‑approval prospects.
New Zealand Passed a Generational Smoking Ban in 2022, But Repealed It Before It Went Into Effect
New Zealand’s coalition government has scrapped a world‑first generational smoking ban that would have barred anyone born after January 2009 from purchasing cigarettes. The repeal, driven by a deal with New Zealand First, aims to preserve roughly $600 million USD in tobacco revenue for...
Earlier Hospice Election Could Save Medicare $1.5B Yearly
Medicare could save between $1.19 billion and $1.5 billion annually if eligible beneficiaries elected hospice five days earlier, according to a new analysis by the Research Institute for Home Care and ATI Advisory. The study examined beneficiaries who entered hospice within eight...
Hospitals Are Leading the Way to a Healthier America
More than 1,000 hospital and health‑system executives gathered in Washington for the American Hospital Association’s 2026 Annual Membership Meeting, pressing lawmakers to safeguard access to high‑quality, affordable care. Speakers highlighted hospitals’ unique position to advocate for patients and to lead...
The Road Ahead—What’s Next for Host Cell Protein Analytics?
Advanced LC‑MS strategies are reshaping host cell protein (HCP) analytics, moving beyond the semi‑quantitative limits of traditional ELISA. Data‑independent acquisition (DIA) offers broad relative profiling, while stable‑isotope‑labeled (SIL) peptides provide absolute quantification for high‑risk HCPs. Integrating DIA, SIL, and ELISA...
Coloplast Lifts FY Outlook as H1 Profit Rises 6% to DKK2.81bn
Coloplast announced first‑half net profit before special items of DKK2.81 billion, up 6% year‑over‑year, and lifted its full‑year organic growth outlook to 5‑6% in constant currencies. The revised guidance reflects better‑than‑expected earnings and a focus on cash‑flow optimization for shareholders.
The Brand-Driven Flywheel: Igniting Growth Through a Simple Patient Experience
The article argues that legacy patient‑support models are outdated and proposes direct‑to‑patient (DTP) platforms as a brand‑driven flywheel for growth. DTP unifies access, fulfillment and support into a single, tech‑enabled journey, cutting prior‑authorization delays and improving adherence. With specialty drugs...
Health Literacy’s Impacts
A 2024 University of Michigan poll of adults 50 and older shows health providers remain the top source of medical information, with 81% turning to clinicians and 58% also searching the web. While most respondents feel confident handling health data,...
Study Finds Habitual Coffee Alters Gut Microbiome and Boosts Cognitive Performance
Researchers at University College Cork completed a double‑blind trial of 62 Irish adults that linked daily coffee consumption to distinct shifts in gut microbiota and measurable gains on cognitive tests. The findings, registered under ClinicalTrials.gov IDs NCT05927038 and NCT05927103, could...
Preparing for Medicaid Cuts and the Imperial Health Boomerang
The One Big Beautiful Bill Act proposes sweeping Medicaid eligibility cuts that jeopardize the Ryan White Part A HIV safety‑net, which provides free care to low‑income and undocumented patients. Fixed federal funding for the program cannot absorb the expected surge in demand, leaving thousands at...
AJMC® in the Press, April 24, 2026
AJMC highlighted four peer‑reviewed studies that expose cost‑driving inefficiencies in Medicare. One shows generic dispensing rates vary widely, suggesting billions in savings if low‑cost drugs are fully utilized. Another reveals Medicare’s wage‑index formula underpays rural hospitals for device‑intensive surgeries. A...
Bispecific Antibodies Are Reshaping Multiple Myeloma Care: Prerna Mewawalla, MD
Bispecific antibodies are rapidly reshaping multiple myeloma treatment by delivering response rates up to 80% in earlier relapse settings, far surpassing the historic 30% seen with conventional therapies. These agents simultaneously bind a myeloma antigen such as BCMA, GPRC5D or...
Pfizer Presents Auristatin S ADC for GPNMB Tumors
Pfizer has unveiled PF-08046033, an antibody‑drug conjugate that links the potent cytotoxic agent auristatin S to an antibody targeting the transmembrane glycoprotein NMB (GPNMB). The ADC is designed to deliver the payload directly into GPNMB‑expressing tumors, potentially widening the therapeutic...
Pharma Industry Faces Long Haul to Get Return on Investment From AI
The pharmaceutical sector is confronting a prolonged timeline before artificial intelligence delivers a clear return on investment. While AI tools have accelerated early‑stage drug discovery, most companies still grapple with data integration, regulatory compliance, and the high cost of talent....
Closing the Pediatric Care Gap Through Primary Care Reimbursement Reform: Chris Johnson, MBA
Chris Johnson, MBA, founder of Bluebird Kids Health, warns that many U.S. communities are becoming pediatric care deserts, with as few as one pediatrician for every 6,000‑7,000 children. The shortage forces families, especially those on Medicaid, to seek routine care...
Modified CRISPR Tool Targets Down Syndrome Mutation
Researchers at Beth Israel Deaconess Medical Center and Harvard Medical School have engineered a modified CRISPR system that inserts the long non‑coding RNA XIST into one copy of chromosome 21, silencing the extra genetic material that causes Down syndrome. The new...
FTC, US Anesthesia Partners Reach Settlement in Texas Price Collusion Case
The Federal Trade Commission reached a confidential settlement with U.S. Anesthesia Partners (USAP), a private‑equity‑backed anesthesia provider, over allegations it consolidated the Texas market and raised prices. USAP denied wrongdoing but agreed to settle to avoid costly litigation, while the...
‘We Need to Change the Conversation’: Tips for Assessing CV Risk in South Asian Adults
South Asian adults experience higher and earlier cardiovascular risk than other groups, prompting calls for earlier screening. Endocrinologist Rachna Relwani recommends coronary calcium scans beginning at age 40‑45 regardless of BMI, and adding Lp‑a, ApoB and CRP to standard labs....
Re: Sexual Misconduct: “Deeply Alarming” Rise in Cases Against Doctors
The Working Party on Sexual Misconduct in Surgery responded to a BMJ report on a rise in doctor‑related sexual misconduct cases, arguing that the increase in reported incidents reflects greater awareness and psychological safety rather than a worsening problem. The...
Avalyn Pharma (AVLN) IPO Deck
Avalyn Pharma, a clinical‑stage biopharmaceutical firm, unveiled its IPO deck on April 24, 2026, highlighting a pipeline of inhaled therapies for rare, high‑unmet‑need respiratory diseases. The company seeks to list on a U.S. exchange, positioning itself to raise capital for advancing Phase 2...